Evidence map›Paper›PMID 32064909›Full record

ArticleJournal of diabetes science and technology2021

Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM.

Ralph Ziegler, Lutz Heinemann, Guido Freckmann, Oliver Schnell, Rolf Hinzmann, Bernd Kulzer

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. A Podcast on the Use of CGM in Optimizing Type 2 Diabetes Management with Non-intensive Insulin Treatment in the Primary Care Setting.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  13. Article
  14. Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Review
  15. Observational
  16. Article
  17. Article
  18. The Authors Respond.Journal of managed care & specialty pharmacy · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ralph ZieglerDiabetes Clinic for Children and Adolescents, Muenster, Germany.ORCID 0000-0002-2373-3720
Lutz HeinemannScience Consulting in Diabetes GmbH, Neuss, Germany.ORCID 0000-0003-2493-1304
Guido FreckmannInstitut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Germany.ORCID 0000-0002-0406-9529
Oliver SchnellForschergruppe Diabetes e.V., Helmholtz Zentrum, Munich, Germany.
Rolf HinzmannRoche Diabetes Care GmbH, Mannheim, Germany.
Bernd KulzerDiabetes Center Bad Mergentheim, Research Institute of the Diabetes Academy, Bad Mergentheim, University Bamberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to the continuous use, the intermittent use of continuous glucose monitoring (CGM) is an application of CGM, expanding the typical medical use cases. There are a variety of reasons and occasions that speak in favor of using CGM only for a limited time. To date, these circumstances have not been sufficiently discussed. In this article, we define discontinuous or intermittent CGM use, provide reasons for using it, and expand on the benefits and possibilities of using CGM on a temporary basis. We aim to draw attention to this important topic in the discussion of CGM use and give examples for a different method of CGM use. As well, we would like to foster the allocation of CGM to the right patient groups and indications, especially in cases of limited resources. From a global point of view, intermittent CGM use is more likely to occur than continuous use, primarily for economic reasons.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringHumansBlood GlucoseCGMcontinuous glucose monitoringdiabetesintermittent use

Identifiers

PMID32064909
PMCPMC8120049

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.